Research

Hormonal

Semaglutide (2.4 mg once-weekly) significantly reduces the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its components (steatosis, inflammation, ballooning) in patients with overweight/obesity and type 2 diabetes compared to placebo.

If you have overweight/obesity and type 2 diabetes, semaglutide (2.4 mg weekly) is a clinically proven treatment to significantly reduce liver fat, inflammation, and scarring (MASH/MASLD) compared to placebo. This is particularly relevant if lifestyle changes alone have not resolved liver issues. The treatment involves a weekly injection and is supported by strong statistical evidence from large clinical trials.

GoodSupportsHIGH confidence
Participants receiving semaglutide were also likely to have a less severe SomaSignal-derived MASLD stage vs. placebo at week 68 (OR [95% CI]) for semaglutide 2.4 mg: STEP 1 (5.26 [3.59, 7.72]); STEP 2 (4.90 [2.86, 8.40]); p <0.0001)
Jörn M. Schattenberg et al. · JHEP Reports · 2025

Why this rating

Post hoc analysis of large, randomized, placebo-controlled phase III trials (STEP 1 & 2) with strong statistical significance (p<0.0001), though using a proteomic surrogate (SomaSignal) rather than primary biopsy endpoints for the main claim.

Source

Proteomic signatures reflect effects of semaglutide treatment for MASH

Jörn M. Schattenberg et al. · JHEP Reports · 2025

DOI 10.1016/j.jhepr.2025.101521

rct · n=2184Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →